Intermediate Grade/Aggressive Grade NHL


The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be... Continue Reading

FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma (January 19, 2015)

The U. S. Food and Drug Administration has granted Fast Track designation the synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published... Continue Reading

Zevalin Plus Nonmyeloablative Allogeneic Transplantation Effective in High-Risk B-Cell NHL (March 29, 2013)

The addition of Zevalin® (ibritumomab tiuxetan) to nonmyeloablative allogeneic transplantation (NMAT) is safe and produces early responses and prolonged disease control in high-risk patients with B-cell... Continue Reading

Men, Fertility, and Cancer (July 6, 2012)

Men who confront a cancer diagnosis before beginning or completing their families may have many questions about how cancer treatment will affect their ability to have children in the future. The good news... Continue Reading

Coping with Taste Changes (June 4, 2012)

If you’re undergoing chemotherapy, biologic therapy, or radiation to the head or neck area, one of the side effects you may experience is a change in how things taste. While this may seem like a minor... Continue Reading

Medical Costs Higher Among Survivors (June 21, 2011)

Cancer survivors tend to pay substantially more in annual medical costs compared with people who have never had cancer. These findings were recently reported in Cancer. A significant number of adults in... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment... Continue Reading

Relapsed Aggressive NHL (March 22, 2004)

Overview Patients with aggressive non-Hodgkin’s lymphoma (NHL) that has progressed after initial treatment have what is called relapsed disease. Patients with relapsed NHL can be divided into two... Continue Reading

Stage IIE-IV Aggressive NHL (March 22, 2004)

Overview Patients classified as having stage IIE–IV disease are considered to have advanced stage non-Hodgkin’s lymphoma. Aggressive lymphomas are classified according to two systems: the Revised... Continue Reading

Stage I-II Aggressive NHL (March 22, 2004)

Overview Patients classified as having stage I, IE, or IIA non-Hodgkin’s lymphoma (NHL) are considered to have localized disease. More than half of these patients can be cured with initial treatment. Aggressive... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS